BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 34815788)

  • 1. CST6 protein and peptides inhibit breast cancer bone metastasis by suppressing CTSB activity and osteoclastogenesis.
    Li X; Liang Y; Lian C; Peng F; Xiao Y; He Y; Ma C; Wang Y; Zhang P; Deng Y; Su Y; Luo C; Kong X; Yang Q; Liu T; Hu G
    Theranostics; 2021; 11(20):9821-9832. PubMed ID: 34815788
    [No Abstract]   [Full Text] [Related]  

  • 2. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
    Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
    Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
    [No Abstract]   [Full Text] [Related]  

  • 3. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
    Sung B; Oyajobi B; Aggarwal BB
    Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential secretome analysis reveals CST6 as a suppressor of breast cancer bone metastasis.
    Jin L; Zhang Y; Li H; Yao L; Fu D; Yao X; Xu LX; Hu X; Hu G
    Cell Res; 2012 Sep; 22(9):1356-73. PubMed ID: 22688893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
    Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
    Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
    Gai D; Chen JR; Stewart JP; Nookaew I; Habelhah H; Ashby C; Sun F; Cheng Y; Li C; Xu H; Peng B; Garg TK; Schinke C; Thanendrarajan S; Zangari M; Chen F; Barlogie B; van Rhee F; Tricot G; Shaughnessy JD; Zhan F
    J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35881476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Andrographolide suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
    Zhai ZJ; Li HW; Liu GW; Qu XH; Tian B; Yan W; Lin Z; Tang TT; Qin A; Dai KR
    Br J Pharmacol; 2014 Feb; 171(3):663-75. PubMed ID: 24125472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cysteine cathepsin activity suppresses osteoclastogenesis of myeloid-derived suppressor cells in breast cancer.
    Edgington-Mitchell LE; Rautela J; Duivenvoorden HM; Jayatilleke KM; van der Linden WA; Verdoes M; Bogyo M; Parker BS
    Oncotarget; 2015 Sep; 6(29):27008-22. PubMed ID: 26308073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathepsin G enhances mammary tumor-induced osteolysis by generating soluble receptor activator of nuclear factor-kappaB ligand.
    Wilson TJ; Nannuru KC; Futakuchi M; Sadanandam A; Singh RK
    Cancer Res; 2008 Jul; 68(14):5803-11. PubMed ID: 18632634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TBX2 represses CST6 resulting in uncontrolled legumain activity to sustain breast cancer proliferation: a novel cancer-selective target pathway with therapeutic opportunities.
    D'Costa ZC; Higgins C; Ong CW; Irwin GW; Boyle D; McArt DG; McCloskey K; Buckley NE; Crawford NT; Thiagarajan L; Murray JT; Kennedy RD; Mulligan KA; Harkin DP; Waugh DJ; Scott CJ; Salto-Tellez M; Williams R; Mullan PB
    Oncotarget; 2014 Mar; 5(6):1609-20. PubMed ID: 24742492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.
    Chen Y; Zheng J; Mo L; Chen F; Li R; Wang Y; Liang Q; Chen Z; Dai W; Chen L; Yan P; Zhou H; Li X
    Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epiberberine inhibits bone metastatic breast cancer-induced osteolysis.
    Wei C; Shi M; Wang Z; Lan W; Feng N; Zhang F; Liu J; Lang JY; Lin W; Ma W
    J Ethnopharmacol; 2024 Jun; 327():118039. PubMed ID: 38479545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quetiapine inhibits osteoclastogenesis and prevents human breast cancer-induced bone loss through suppression of the RANKL-mediated MAPK and NF-κB signaling pathways.
    Wang H; Shen W; Hu X; Zhang Y; Zhuo Y; Li T; Mei F; Li X; Xiao L; Chu T
    Breast Cancer Res Treat; 2015 Feb; 149(3):705-14. PubMed ID: 25667102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-11 is essential in promoting osteolysis in breast cancer bone metastasis via RANKL-independent activation of osteoclastogenesis.
    Liang M; Ma Q; Ding N; Luo F; Bai Y; Kang F; Gong X; Dong R; Dai J; Dai Q; Dou C; Dong S
    Cell Death Dis; 2019 Apr; 10(5):353. PubMed ID: 31040267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SREBP-2 aggravates breast cancer associated osteolysis by promoting osteoclastogenesis and breast cancer metastasis.
    Jie Z; Xie Z; Xu W; Zhao X; Jin G; Sun X; Huang B; Tang P; Wang G; Shen S; Qin A; Fan S
    Biochim Biophys Acta Mol Basis Dis; 2019 Jan; 1865(1):115-125. PubMed ID: 30394316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological evidence for the bone-autonomous contribution of the NFκB/β-catenin axis to breast cancer related osteolysis.
    Marino S; Bishop RT; Logan JG; Mollat P; Idris AI
    Cancer Lett; 2017 Dec; 410():180-190. PubMed ID: 28965856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
    Marino S; Bishop RT; Mollat P; Idris AI
    Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cathepsin B as a potential cystatin M/E target in the mouse hair follicle.
    Oortveld MAW; van Vlijmen-Willems IMJJ; Kersten FFJ; Cheng T; Verdoes M; van Erp PEJ; Verbeek S; Reinheckel T; Hendriks WJAJ; Schalkwijk J; Zeeuwen PLJM
    FASEB J; 2017 Oct; 31(10):4286-4294. PubMed ID: 28596234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-κB/bone remodeling factors signaling.
    Xu Y; Zhang S; Liao X; Li M; Chen S; Li X; Wu X; Yang M; Tang M; Hu Y; Li Z; Yu R; Huang M; Song L; Li J
    Mol Cancer; 2021 Jul; 20(1):98. PubMed ID: 34325714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Knockdown of Bone Morphogenetic Proteins Type 1a Receptor (BMPR1a) in Breast Cancer Cells Protects Bone from Breast Cancer-Induced Osteolysis by Suppressing RANKL Expression.
    Liu Y; Zhang RX; Yuan W; Chen HQ; Tian DD; Li H; Jiang X; Deng ZL; Wang Y
    Cell Physiol Biochem; 2018; 45(5):1759-1771. PubMed ID: 29495003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.